Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
4D Molecular Therapeutics (FDMT)
NASDAQ:FDMT
RESEARCH TOOLSreports
Holding FDMT?
Track your performance easily
FDMT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.44 - $36.25
Previous Close$16.82
Volume2.47M
Average Volume (3M)881.78K
Market Cap
$718.22M
Enterprise Value$345.84M
Total Cash (Recent Filing)$541.95M
Total Debt (Recent Filing)$13.66M
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Nov 06, 2024EPS Estimate
-$0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.73
Shares Outstanding51,969,590
10 Day Avg. Volume514,371
30 Day Avg. Volume881,783
Standard Deviation0.34
R-Squared0.15
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.49
Price to Sales (P/S)41.54
Price to Cash Flow (P/CF)-6.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue17.10
Enterprise Value/Gross Profit16.69
Enterprise Value/Ebitda-3.63
Forecast
1Y Price Target
$51.00Price Target Upside269.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
4D Molecular Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEncouraged by the updated 4D-150 Phase 2 PRISM trial analysis in wet AMD from the Population Extension cohort at 24 weeks, which specifically assessed a broader wet AMD patient population.
Financial PerformanceThe company ended 2Q24 with $578mm in cash and equivalents, expected to fund operations into the first half of 2027.
Regulatory ProgressFollowing clinical hold lift on the Ph1/2 INGLAXA study for 4D-310 in Fabry disease cardiomyopathy, FDMT anticipates resuming enrollment in 2H24.
Bears Say
Investor SentimentNew safety signal worsened investor sentiment.
Management CredibilityLack of transparency around a second loading dose impacted management's credibility.
Trial Design ConcernsThe change in trial design raises questions and leads to a lower target price.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
FDMT FAQ
What was 4D Molecular Therapeutics’s price range in the past 12 months?
4D Molecular Therapeutics lowest stock price was $9.44 and its highest was $36.25 in the past 12 months.
What is 4D Molecular Therapeutics’s market cap?
Currently, no data Available
When is 4D Molecular Therapeutics’s upcoming earnings report date?
4D Molecular Therapeutics’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were 4D Molecular Therapeutics’s earnings last quarter?
4D Molecular Therapeutics released its earnings results on Aug 08, 2024. The company reported -$0.63 earnings per share for the quarter, beating the consensus estimate of -$0.684 by $0.054.
Is 4D Molecular Therapeutics overvalued?
According to Wall Street analysts 4D Molecular Therapeutics’s price is currently Undervalued.
Does 4D Molecular Therapeutics pay dividends?
4D Molecular Therapeutics does not currently pay dividends.
What is 4D Molecular Therapeutics’s EPS estimate?
4D Molecular Therapeutics’s EPS estimate is -$0.67.
How many shares outstanding does 4D Molecular Therapeutics have?
4D Molecular Therapeutics has 51,969,590 shares outstanding.
What happened to 4D Molecular Therapeutics’s price movement after its last earnings report?
4D Molecular Therapeutics reported an EPS of -$0.63 in its last earnings report, beating expectations of -$0.684. Following the earnings report the stock price went up 0.475%.
Which hedge fund is a major shareholder of 4D Molecular Therapeutics?
Among the largest hedge funds holding 4D Molecular Therapeutics’s share is RA Capital Management. It holds 4D Molecular Therapeutics’s shares valued at 107M.
---
4D Molecular Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.00 (269.03% Upside)
$51.00 (269.03% Upside)
Hedge Fund Trend
Decreased
By 106.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
75.92%
Trailing 12-Months
Company Description
4D Molecular Therapeutics
4D Molecular Therapeutics Inc is a development stage precision gene therapy company. It engages in developing a broad pipeline of transformative gene therapy product candidates designed to treat patients suffering from lysosomal storage diseases, lung diseases, muscular dystrophies, and ophthalmic diseases. The AAV vectors are designed to provide targeted delivery by routine clinical routes, efficient transduction, reduced immunogenicity and resistance to pre-existing antibodies which enable to develop gene therapies.
---
FDMT Stock 12 Month Forecast
Average Price Target
$51.00
▲(269.03% Upside)
Technical Analysis
Best Analysts Covering FDMT
1 Year
1 Year Success Rate
9/17 ratings generated profit
1 Year Average Return
+5.45%
assigned a buy rating 2 days ago
Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of +5.45% per trade.
---